Lupin launches generic psoriasis drug in US
New Delhi: Drug firm Lupin said it has launched its Clobetasol Propionate spray, used for treating plaque psoriasis, in the American market.
The company has launched Clobetasol Propionate spray, 0.05 percent, after receiving an approval for it from the United States Food and Drug Administration (FDA) earlier, Lupin said in a statement.
The company's product is the generic version of Galderma Laboratories, LP's Clobex spray in the same strength, it added.
As per IQVIA MAT January 2018 data, the spray had an annual sales of around USD 30.5 million in the US.
The spray is "indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20 percent body surface area in patients 18 years of age or older," Lupin said.
American marketClobetasol PropionateClobex sprayGalderma Laboratoriesgenericgeneric versionlaunchesLupinplaque psoriasispsoriasis drugsprayUnited States Food and Drug AdministrationUS
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd